2nd Abu Dhabi Brain Conference 2022 Program Book

TECFIDERA effectively impacts disease activity in the long term. 1-5 FOR THE TREATMENT OF ADULT PATIENTS WITH RRMS References: 1. TECFIDERA SmPC; please refer to the approved SmPC in your country. 2. Pardo G, Jones DE. The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. J Neurol. 2017;264(12):2351-2374. 3. Gold R, et al. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: interim analysis of ENDORSE, a randomized extension study. Mult Scler. 2017;23(2):253-265. 4. Gold R, et al. Sustained effect of delayed-release dimethyl fumarate in newly diagnosed patients with relapsing-remitting multiple sclerosis: 6-year interim results from an extension of the DEFINE and CONFIRM studies. Neurol Ther. 2016;5:45-57. 5. Tecfidera Exposure Data 4 March 2021. Biogen Data on File. Biogen-131285 | January 2022